iLab

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced results from an open-label Phase III study of ERBITUX(R)(Cetuximab) plus a taxane and carboplatin in the first-linetreatment for metastatic non-small cell lung cancer (NSCLC). Thestudy did not meet its primary endpoint of progression-freesurvival (PFS) as assessed...

Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In Absolute Bioavailability Study

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 7, 2007 - BioDeliverySciences International, Inc. (Nasdaq:BDSI) announced the results ofa 12 subject, crossover study comparing the absorption of fentanylfrom both single and multiple BEMA(TM) Fentanyl discs, as well asoral and intravenous doses of fentanyl. The data demonstrates thatthe absolute bioavailability (i.e. the total amount absorbed fromthe...

Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study

* Glivec found to dramatically reduce the risk of cancerreturning after surgery for Kit-positive gastrointestinal stromaltumors (GIST) * Patients receiving placebo in this trial will now be offeredGlivec * Global regulatory submissions planned for use of Glivec asadjuvant therapy in GIST patients following surgery to removeprimary tumor * Glivec already approved as ef...

Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returningafter surgery for Kit-positive gastrointestinal stromal tumors(GIST) EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigatorswill begin offering Gleevec(R) (imatinib mesylate)* tablets topatients receiving placebo in a major North American clinical trialafter an interim analysis showed participants with Kit-positiv...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced that a Phase III study of ERBITUX(R) (Cetuximab) plusgemcitabine (a chemotherapy) in patients with locally advancedunresectable or metastatic pancreatic cancer did not meet itsprimary endpoint of improving overall survival. Conducted by the Southwest Oncolo...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

-- First large, randomized Phase III study of ERBITUX withchemotherapy in recurrent and/or metastatic head and neck cancermeets primary endpoint of improving overall survival -- NEW YORK, April 04, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company announcedtoday that a first line Phase III study of ERBITUX(R) (Cetuximab)combined with platinum-base...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone SystemsIncorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) announced today that a first line Phase III study ofERBITUX(R) (Cetuximab) combined with platinum-based chemotherapymet the primary endpoint of increasing overall survival in patientswith recurrent and/or metastatic squamous cell carcinoma of thehead and neck (SCCH...